JRJorge Roig

Jorge Roig

*This is an algorithmically generated author record based on publicly available information.

Jorge Roig has a total of 264 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Lung in Aerotoxic Syndrome

    by Jorge Roig, Susan Michaelis, Jonathan Burdon


  • Irritant-induced Asthma Caused by Aerotoxic Syndrome

    by Jorge Roig, Christian Domingo, Jonathan Burdon, Susan Michaelis

    Purpose Case series on respiratory features of Aerotoxic Syndrome (AS). The term AS has been coined to describe the spectrum of clinical manifestations after aircraft fume events. Among these manifestations, neurological and respiratory symptoms are the most frequently reported complaints. Methods Three cases of AS with relevant respiratory features are presented. Results Cough and shortness of breath for 6 to12 months were the predominant symptoms in the first two cases. The first case also developed neurological symptoms affecting his central nervous system. In the third case, the patient complained for nine years about an unbearable cough triggered by odors, smells, and a variety of indoor and outdoor irritants, among other symptoms of multiple chemical sensitivity. In all three cases, the respiratory symptoms resolved after appropriate treatment. Conclusion Our report aims at raising awareness on AS and calls for actions to improve the management of patients suffering from this syndrome.


  • Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia

    by Forest W. Arnold, Gustavo Lopardo, Timothy L. Wiemken, Robert Kelley, Paula Peyrani, William A. Mattingly, Charles Feldman, Martin Gnoni, Rosemeri Maurici, Julio A. Ramirez, et al.


  • Relación de las profesiones y las condiciones laborales con la neumonía adquirida en la comunidad

    by Jordi Almirall, Mateu Serra-Prat, Ignasi Bolíbar, Elisabet Palomera, Jordi Roig, Ramon Boixeda, Maria Bartolomé, Mari de la Torre, Olga Parra, Antoni Torres


  • Open Access

    Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based case–control study

    by Jordi Almirall, Mateu Serra-Prat, Ignasi Bolíbar, Elisabet Palomera, Jordi Roig, Imma Hospital, Eugenia Carandell, Mercè Agustí, Pilar Ayuso, Andreu Estela, et al.

    Objective: To assess whether passive smoking exposure at home is a risk factor for community-acquired pneumonia (CAP) in adults. Setting: A population-based case-control study was designed in a Mediterranean area with 860 000 inhabitants >14 years of age. Participants: 1003 participants who had never smoked were recruited. Primary and secondary outcome measures: Risk factors for CAP, including home exposure to passive smoking, were registered. All new cases of CAP in a well-defined population were consecutively recruited during a 12-month period. Methods: A population-based case-control study was designed to assess risk factors for CAP, including home exposure to passive smoking. All new cases of CAP in a well-defined population were consecutively recruited during a 12-month period. The subgroup of never smokers was selected for the present analysis. Results: The study sample included 471 patients with CAP and 532 controls who had never smoked. The annual incidence of CAP was estimated to be 1.14 cases×10 –3 inhabitants in passive smokers and 0.90×10 −3 in non-passive smokers (risk ratio (RR) 1.26; 95% CI 1.02 to 1.55) in the whole sample. In participants ≥65 years of age, this incidence was 2.50×10 −3 in passive smokers and 1.69×10 −3 in non-passive smokers (RR 1.48, 95% CI 1.08 to 2.03). In this last age group, the percentage of passive smokers in cases and controls was 26% and 18.1%, respectively (p=0.039), with a crude OR of 1.59 (95% CI 1.02 to 2.38) and an adjusted (by age and sex) OR of 1.56 (95% CI 1.00 to 2.45). Conclusions: Passive smoking at home is a risk factor for CAP in older adults (65 years or more).


  • Open Access

    Relationship between the Use of Inhaled Steroids for Chronic Respiratory Diseases and Early Outcomes in Community-Acquired Pneumonia

    by Jordi Almirall, Ignasi Bolíbar, Mateu Serra-Prat, Elisabet Palomera, Jordi Roig, Imma Hospital, Eugenia Carandell, Mercè Agustí, Pilar Ayuso, Andreu Estela, et al.

    The role of inhaled steroids in patients with chronic respiratory diseases is a matter of debate due to the potential effect on the development and prognosis of community-acquired pneumonia (CAP). We assessed whether treatment with inhaled steroids in patients with chronic bronchitis, COPD or asthma and CAP may affect early outcome of the acute pneumonic episode. Over 1-year period, all population-based cases of CAP in patients with chronic bronchitis, COPD or asthma were registered. Use of inhaled steroids were registered and patients were followed up to 30 days after diagnosis to assess severity of CAP and clinical course (hospital admission, ICU admission and mortality). Of 473 patients who fulfilled the selection criteria, inhaled steroids were regularly used by 109 (23%). In the overall sample, inhaled steroids were associated with a higher risk of hospitalization (OR=1.96, p = 0.002) in the bivariate analysis, but this effect disappeared after adjusting by other severity-related factors (adjusted OR=1.08, p=0.787). This effect on hospitalization also disappeared when considering only patients with asthma (OR=1.38, p=0.542), with COPD alone (OR=4.68, p=0.194), but a protective effect was observed in CB patients (OR=0.15, p=0.027). Inhaled steroids showed no association with ICU admission, days to clinical recovery and mortality in the overall sample and in any disease subgroup. Treatment with inhaled steroids is not a prognostic factor in COPD and asthmatic patients with CAP, but could prevent hospitalization for CAP in patients with clinical criteria of chronic bronchitis.


  • Community-acquired Legionella Pneumonia in the intensive care unit: Impact on survival of combined antibiotic therapy

    by J. Rello, S. Gattarello, J. Souto, J. Sole-Violan, J. Valles, R. Peredo, R. Zaragoza, L. Vidaur, A. Parra, J. Roig


  • Inhaled drugs as risk factors for community-acquired pneumonia

    by J. Almirall, I. Bolíbar, M. Serra-Prat, E. Palomera, J. Roig, I. Hospital, E. Carandell, M. Agustí, P. Ayuso, A. Estela, et al.

    The effect of inhaled drugs in community-acquired pneumonia (CAP) is unclear. This case–control study was designed to determine whether inhaled drugs were risk factors for CAP.All incident cases of confirmed CAP that occurred over 1 yr in patients with chronic bronchitis (CB), chronic obstructive pulmonary disease (COPD) or asthma were included, as well as CB, COPD and asthma controls. Risk factors for CAP and inhaled treatment were recorded during a personal interview.An effect of inhaled drugs on the risk of CAP was observed in COPD and asthma patients after adjusting for the effect of other respiratory diseases and their concomitant treatments. In COPD patients, inhaled steroids had a risk OR of 3.26 (95% CI 1.07–9.98) and in asthma patients inhaled anticholinergics had a risk OR of 8.80 (95% CI 1.02–75.7). In CB patients, no association with CAP was observed for any inhaler. These effects were independent of adjusting variables related to severity and other respiratory and non-respiratory risk factors for CAP, including vaccines. Inhaled β2-adrenergic agonists did not show a significant effect on the risk of CAP in any of the respiratory diseases.Inhaled steroids may favour CAP in COPD patients, whereas anticholinergics may favour CAP in asthma patients. It is difficult to differentiate the effect of inhaled therapy from the effect of COPD or asthma severity on the risk of CAP, and these relationships may not be causal, but could call attention to inhaled therapy in COPD and asthma patients.


  • Open Access

    Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist

    by Jorge Roig, Rosana Hernando, Ramon Mora

    In this article we will review the role of long acting β2-adrenoreceptor agonists and long-acting muscarinic agents in the management of airflow obstruction. We will then focus our attention on indacaterol, one of the new once daily inhaled β2-adrenoreceptor agonists. Pharmacologically this drug is a nearly full β2-agonist without loss of efficacy after prolonged administration. We will also discuss its dosing, safety and tolerability.


  • New evidence of risk factors for community-acquired pneumonia: a population-based study

    by J. Almirall, I. Bolíbar, M. Serra-Prat, J. Roig, I. Hospital, E. Carandell, M. Agustí, P. Ayuso, A. Estela, A. Torres, et al.

    The aim of the present study was to identify risk factors for community-acquired pneumonia (CAP), with special emphasis on modifiable risk factors and those applicable to the general population.A population-based, case–control study was conducted, with a target population of 859,033 inhabitants aged >14 yrs. A total of 1,336 patients with confirmed CAP were matched to control subjects by age, sex and primary centre over 1 yr.In the univariate analysis, outstanding risk factors were passive smoking in never-smokers aged >65 yrs, heavy alcohol intake, contact with pets, households with >10 people, contact with children, interventions on the upper airways and poor dental health. Risky treatments included amiodarone,N-acetylcysteine and oral steroids. Influenza and pneumococcal vaccine, and visiting the dentist were protective factors. Multivariable analysis confirmed cigarette smoking, usual contact with children, sudden changes of temperature at work, inhalation therapy (particularly containing steroids and using plastic pear-spacers), oxygen therapy, asthma and chronic bronchitis as independent risk factors.Interventions for reducing community-acquired pneumonia should integrate health habits and lifestyle factors related to household, work and community, together with individual clinical conditions, comorbidities and oral or inhaled regular treatments. Prevention would include vaccination, dental hygiene and avoidance of upper respiratory colonisation.